Form 4: Director Hilda Scharen-Guivel Sells IRMD Shares

Director Hilda Scharen-Guivel of IRADIMED CORPORATION sold 3,000 shares of common stock at a price of $95.00 per share.

Summary

• Director Hilda Scharen-Guivel executed the sale of 3,000 shares of IRADIMED CORPORATION (IRMD) common stock.
• The transaction occurred on June 4, 2026, at a fixed price of $95.00 per share.
• Following these transactions, the director retains beneficial ownership of 5,598 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a routine disclosure of an insider transaction rather than a fundamental shift in company operations.

Positives

• The director maintains a remaining stake of 5,598 shares, indicating continued alignment with the company's long-term performance.

Negatives

• The sale represents a reduction in the director's direct equity position in the company.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in future growth, though it is often related to personal financial planning.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that director stock sales are common occurrences for portfolio rebalancing and do not necessarily reflect a change in the company's fundamental health or strategic direction.

Comparison to Industry Standards

• Director equity transactions are standard regulatory filings and are consistent with corporate governance practices across the medical device sector.

Stakeholder Impact

• Minimal impact expected on shareholders as this is a standard disclosure of director activity.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

IRMD, IRADIMED, Insider Trading, Form 4, Director Sale, Equity Ownership